Optimization and in vitro evaluation of ziprasidone nanosuspensions produced by a top-down approach

Müller, 2011, State of the art of nanocrystals - special features, production, nanotoxicology aspects and intracellular delivery, Eur. J. Pharm. Biopharm., 78, 1, 10.1016/j.ejpb.2011.01.007 Gao, 2012, Drug nanocrystals: in vivo performances, J. Control. Release, 160, 418, 10.1016/j.jconrel.2012.03.013 Ahuja, 2015, Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension, Int. J. Pharm., 478, 540, 10.1016/j.ijpharm.2014.12.003 Müller, 2001, Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future, Adv. Drug Deliv. Rev., 47, 3, 10.1016/S0169-409X(00)00118-6 Dolenc, 2009, Advantages of celecoxib nanosuspension formulation and transformation into tablets, Int. J. Pharm., 376, 204, 10.1016/j.ijpharm.2009.04.038 Quan, 2012, A novel surface modified nitrendipine nanocrystals with enhancement of bioavailability and stability, Int. J. Pharm., 430, 366, 10.1016/j.ijpharm.2012.04.025 Chan, 2011, Production methods for nanodrug particles using the bottom-up approach, Adv. Drug Deliv. Rev., 63, 406, 10.1016/j.addr.2011.03.011 Keck, 2006, Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation, Eur. J. Pharm. Biopharm., 62, 3, 10.1016/j.ejpb.2005.05.009 Karakucuk, 2016, Preparation of ritonavir nanosuspensions by microfluidization using polymeric stabilizers: I. A Design of Experiment approach, Eur. J. Pharm. Sci., 95, 111, 10.1016/j.ejps.2016.05.010 Bobes, 2004, Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain, Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 28, 1287, 10.1016/j.pnpbp.2004.06.017 Brinholi, 2016, Clozapine and olanzapine are better antioxidants than haloperidol, Quetiapine, Risperidone and ziprasidone in in vitro models, Biomed. Pharmacother., 81, 411, 10.1016/j.biopha.2016.02.047 Coplan, 2013, Tardive dyskinesia from atypical antipsychotic agents in patients with mood disorders in a clinical setting, J. Affect. Disord., 150, 868, 10.1016/j.jad.2013.04.053 Thombre, 2015, Pharmacoscintigraphy studies to assess the feasibility of a controlled release formulation of ziprasidone, J. Control. Release, 213, 10, 10.1016/j.jconrel.2015.06.032 Teeranachaideekul, 2008, Development of ascorbyl palmitate nanocrystals applying the nanosuspension technology, Int. J. Pharm., 354, 227, 10.1016/j.ijpharm.2007.11.062 Guo, 2013, Development and in vivo/in vitro evaluation of novel herpetrione nanosuspension, Int. J. Pharm., 441, 227, 10.1016/j.ijpharm.2012.11.039 Verma, 2011, Physical stability of nanosuspensions: investigation of the role of stabilizers on Ostwald ripening, Int. J. Pharm., 406, 145, 10.1016/j.ijpharm.2010.12.027 George, 2013, Identifying the correlation between drug/stabilizer properties and critical quality attributes (CQAs) of nanosuspension formulation prepared by wet media milling technology, Eur. J. Pharm. Sci., 48, 142, 10.1016/j.ejps.2012.10.004 Oktay, 2018, Dermal flurbiprofen nanosuspensions: optimization with design of experiment approach and in vitro evaluation, Eur. J. Pharm. Sci., 10.1016/j.ejps.2018.07.009 Tuomela, 2016, Production, applications and in vivo fate of drug nanocrystals, J. Drug Deliv. Sci. Technol., 34, 21, 10.1016/j.jddst.2016.02.006 Dewalkar, 2012 Bera, 2015, Mucoadhesive-floating zinc-pectinate-sterculia gum interpenetrating polymer network beads encapsulating ziprasidone HCl, Carbohydr. Polym., 131, 108, 10.1016/j.carbpol.2015.05.042 Wang, 2013, Stability of nanosuspensions in drug delivery, J. Control. Release, 172, 1126, 10.1016/j.jconrel.2013.08.006 Hong, 2014, Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation, Int. J. Pharm., 477, 251, 10.1016/j.ijpharm.2014.10.044 Chaubal, 2008, Conversion of nanosuspensions into dry powders by spray drying: a case study, Pharm. Res. (N. Y.), 25, 2302, 10.1007/s11095-008-9625-0 Dressman, 2000, In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs, Eur. J. Pharm. Sci., 10.1016/S0928-0987(00)00181-0 Miceli, 2007, The effect of food on the absorption of oral ziprasidone, Psychopharmacol. Bull., 40, 58 Thombre, 2012, In vitro and in vivo characterization of amorphous, nanocrystalline, and crystalline ziprasidone formulations, Int. J. Pharm., 428, 8, 10.1016/j.ijpharm.2012.02.004 Klein, 2010, The use of biorelevant dissolution media to forecast the in vivo performance of a drug, AAPS J., 12, 397, 10.1208/s12248-010-9203-3 Sinha, 2013, Bottom-up approaches for preparing drug nanocrystals: formulations and factors affecting particle size, Int. J. Pharm., 453, 126, 10.1016/j.ijpharm.2013.01.019 Zhang, 2010, DDSolver: an add-in program for modeling and comparison of drug dissolution profiles, AAPS J., 12, 263, 10.1208/s12248-010-9185-1 Dening, 2016, Silica encapsulated lipid-based drug delivery systems for reducing the fed/fasted variations of ziprasidone in vitro, Eur. J. Pharm. Biopharm., 101, 33, 10.1016/j.ejpb.2016.01.010